Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Michael O'Riordan

August 23, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Todd Neale

June 22, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Daily News

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

L.A. McKeown

July 29, 2015

News Daily News

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

L.A. McKeown

July 29, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Daily News

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Yael L. Maxwell

June 05, 2015

Advertisement

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content